Literature DB >> 8931208

Comparing methods for calculating confidence intervals for vaccine efficacy.

M Ewell1.   

Abstract

A method is introduced for computing a Bayesian 95 per cent posterior probability region for vaccine efficacy. This method assumes independent vague gamma prior distributions for the incidence rates on each arm of the trial, and a Poisson likelihood for the counts of incident cases of infection. The approach is similar in spirit to the Bayesian analysis of the binomial risk ratio described by Aitchison and Bacon-Shone. However, the focus of our interest is not on incorporating prior information into the design of trials for efficacy, but rather on evaluating whether or not the Bayesian approach with vague prior information produces comparable results to a frequentist approach. A review of methods for constructing exact and large sample intervals for vaccine efficacy is provided as a framework for comparison. The confidence interval methods are assessed by comparing the size and power of tests of vaccine efficacy in proposed intermediate sized randomized double blinded placebo controlled trials.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931208     DOI: 10.1002/(SICI)1097-0258(19961115)15:21<2379::AID-SIM457>3.0.CO;2-L

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  Dramatic decline of serogroup C meningococcal disease incidence in Catalonia (Spain) 24 months after a mass vaccination programme of children and young people.

Authors:  L Salleras; A Domínguez; G Prats; I Parron; P Muñoz
Journal:  J Epidemiol Community Health       Date:  2001-04       Impact factor: 3.710

2.  Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.

Authors:  Matti Lehtinen; Camilla Lagheden; Tapio Luostarinen; Tiina Eriksson; Dan Apter; Katja Harjula; Marjo Kuortti; Kari Natunen; Johanna Palmroth; Tiina Petäjä; Eero Pukkala; Mari Siitari-Mattila; Frank Struyf; Pekka Nieminen; Jorma Paavonen; Gary Dubin; Joakim Dillner
Journal:  BMJ Open       Date:  2017-08-18       Impact factor: 2.692

3.  An agent-based model of dengue virus transmission shows how uncertainty about breakthrough infections influences vaccination impact projections.

Authors:  T Alex Perkins; Robert C Reiner; Guido España; Quirine A Ten Bosch; Amit Verma; Kelly A Liebman; Valerie A Paz-Soldan; John P Elder; Amy C Morrison; Steven T Stoddard; Uriel Kitron; Gonzalo M Vazquez-Prokopec; Thomas W Scott; David L Smith
Journal:  PLoS Comput Biol       Date:  2019-03-20       Impact factor: 4.475

4.  Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial.

Authors:  Matti Lehtinen; Camilla Lagheden; Tapio Luostarinen; Tiina Eriksson; Dan Apter; Anne Bly; Penelope Gray; Katja Harjula; Kaisa Heikkilä; Mari Hokkanen; Heidi Karttunen; Marjo Kuortti; Pekka Nieminen; Mervi Nummela; J Paavonen; Johanna Palmroth; Tiina Petäjä; Eero Pukkala; Anna Soderlund-Strand; Ulla Veivo; Joakim Dillner
Journal:  BMJ Open       Date:  2021-12-30       Impact factor: 2.692

5.  Confidence interval estimation for vaccine efficacy against COVID-19.

Authors:  Qinyu Wei; Peng Wang; Ping Yin
Journal:  Front Public Health       Date:  2022-08-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.